Type of Study |
Study Description |
Status |
Parkinson disease
non-dopaminergic Imaging |
Many of the non-motor symptoms (lightheadedness, fatigue, depression, changes in thinking or memory) in Parkinson disease have been shown to be related to changes in other neurochemical systems outside the dopamine system. These imaging studies evaluate the neurochemical changes in the brain that may be associated with the non-motor symptoms of Parkinson disease. Individuals with Parkinson disease at various stages of disease are eligible for these studies. |
Currently enrolling |
PPMI Pre-Motor Arm |
The pre-motor arm of PPMI will enroll participants who do not have Parkinson’s disease and are living with one of three potential risk factors for PD. If you do not have a diagnosis of Parkinson disease and are 60 years of age or older you can participate in the hyposmic (smell testing) arm of the study by going to: michaeljfox.org/takethesmellsurvery or by contacting the call center (877) 525 PPMI. For more information go to the press release by clicking here |
Currently enrolling |
PPMI: Parkinson Progression Marker Intitiative |
PPMI is an observational, multi-center study sponsored by the Michael J Fox Foundation to assess biomarkers for disease progression. The five year study involves evaluation of clinical features, brain imaging and other biomarkers in individuals with Parkinson disease and healthy volunteers.
(www.ppmi-info.org) |
Enrollment Closed |
SURE-PD |
This study is designed to test the safety and efficacy of inosine, a medication with disease modifying potential, in Parkinson disease. (www.pdtrials.org/en/browse/all/view/259) |
Enrollment Closed |
MOTION study |
Sponsored by EMD-Serono, this study will evaluate the efficacy and safety of safinamide as add-on therapy in patients with early Parkinson disease treated with a dopamine agonist. (www.pdtrials.org/en/browse/all/view/276) |
Enrollment Closed |
| CONFIDENT |
This study investigates the safety, tolerability, and efficacy of the Phytopharm investigational medication Cogane on symptoms of early PD for individuals on no other PD medications. |
Enrollment Closed |
| P05664 |
Sponsored by Merck, this phase 3 trial evaluates the efficacy and safety of the non-dopaminergic medication preladenant in early PD. |
Enrollment Closed |
QE3 evaluating CoEnzyme Q10 as a potential neuroprotective agent |
The primary objective of this study is to evaluate if individuals treated with CoEnzyme Q10 have a slower progression of their Parkinson disease. CoEnzyme Q10 is an antioxidant being evaluated in subjects with early untreated Parkinson disease. |
Enrollment Closed |
NET-PD: Evaluating creatine as a potential neuroprotective agent |
This study will assess creatine as a potential agent to slow the progression of Parkinson disease. Creatine is a widely used dietary supplement which is thought to improve exercise performance. It has been shown to be well-tolerated and may have some ability to protect brain cells. |
Enrollment Closed |
| STEADY-PD |
This trial is designed to investigate the safety and tolerability of Dynacirc CR (Isradipine) in early PD and to obtain preliminary evidence of slowing of PD symptoms. |
Enrollment Closed |
SETTLE study |
Sponsored by EMD-Serono, this study will evaluate the efficacy and safety of safinamide in PD patients experiencing motor fluctuations, as an add-on to levodopa. |
Enrollment Closed |
DatSCAN imaging: Evaluating dopamine transporter imaging in PD patients |
This imaging study is sponsored by GE Healthcare and evaluates the effect of dopamine transporter imaging on clinical management decisions. Individuals with clinically uncertain Parkinsonism or an illness with similar symptoms are eligible for participation. |
Enrollment Closed |
PRECEPT imaging study |
This is a long term dopamine transporter SPECT imaging study for individuals who have previously participated in the PRECEPT study. Imaging assessments provide a means for monitoring disease progression and evaluating factors that influence disease progression. |
Enrollment Closed |
ANAM-PD |
This study is designed to evaluate cognition in individuals diagnosed with Parkinson disease. Subjects will undergo a computerized test of cognition (ANAM-PD) in addition to standardized tests of memory and thinking, the results will be compared to age matched healthy participants |
Enrollment Closed |
SPIN-PD: A PD observational study |
The objective of this study is to determine whether blood sampling using a technique called biospectroscopy can distinguish subjects with Parkinson disease from healthy controls. |
Enrollment Closed |
